B. Metzler seel. Sohn & Co. AG raised its position in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 74.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,784 shares of the pharmacy operator's stock after acquiring an additional 52,785 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in CVS Health were worth $12,805,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in CVS. BlackRock Inc. acquired a new position in CVS Health in the 2nd quarter valued at $12,747,462,000. Norges Bank acquired a new stake in CVS Health during the 4th quarter worth $1,666,265,000. Bank of America Corp DE boosted its stake in CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock worth $2,398,868,000 after purchasing an additional 13,836,701 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator's stock worth $1,473,270,000 after buying an additional 12,233,675 shares in the last quarter. Finally, Pzena Investment Management LLC acquired a new stake in shares of CVS Health in the second quarter valued at about $1,217,558,000. 80.66% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities analysts recently weighed in on CVS shares. Sanford C. Bernstein boosted their price target on shares of CVS Health from $94.00 to $106.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 12th. HSBC reiterated a "hold" rating and issued a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Wall Street Zen upgraded CVS Health from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 8th. TD Cowen upped their price target on CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, May 11th. Finally, Royal Bank Of Canada lifted their price objective on CVS Health from $107.00 to $113.00 and gave the stock an "outperform" rating in a research report on Thursday, July 9th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $107.17.
Get Our Latest Analysis on CVS Health
CVS Health Trading Down 0.4%
CVS opened at $97.20 on Thursday. The stock has a market capitalization of $124.31 billion, a PE ratio of 25.71, a P/E/G ratio of 0.95 and a beta of 0.59. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.66 and a current ratio of 0.87. The business's 50 day moving average price is $101.09 and its 200 day moving average price is $89.96.
CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The company had revenue of $106.10 billion for the quarter, compared to the consensus estimate of $100.03 billion. During the same quarter in the previous year, the business earned $1.81 earnings per share. The company's revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.
CVS Health Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a $0.665 dividend. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health's dividend payout ratio is presently 70.37%.
CVS Health Company Profile
(
Free Report)
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
Featured Articles
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
